Latest Pharmacy Operations News

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.

Green Cross Health (NZX: GXH) has acknowledged discussions with third parties about a possible sale of its Medical division but emphasised that no transaction is guaranteed. The company remains committed to updating shareholders as the situation develops.

Pharmx Technologies has entered a multi-year strategic alliance with Sigma Healthcare, becoming the preferred EDI provider for Sigma and Chemist Warehouse across Australia and New Zealand, while Sigma takes a significant equity stake.

Epsilon Healthcare has posted a record $2.891 million in receipts for the December 2025 quarter, nearly doubling year-on-year revenue and marking a significant turnaround with its recent ASX reinstatement.

Epsilon Healthcare has posted its highest-ever quarterly receipts of $2.919 million, reflecting a robust turnaround since exiting voluntary administration in mid-2024. The company’s strategic sale and leaseback deal has also enabled significant debt reduction, setting the stage for sustained growth.

Epsilon Healthcare reports a strong rebound with a 73% revenue increase in the June quarter, driven by contract manufacturing and new pharmacy operations. The company is emerging from restructuring with renewed financial strength and growth prospects.

The Supreme Court of New South Wales has approved the merger scheme between Washington H. Soul Pattinson and Brickworks, paving the way for a new ASX-listed entity, Topco. Shareholders will soon exchange their Soul Patts shares for Topco shares as trading transitions next week.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.

Washington H. Soul Pattinson and Brickworks announce a conditional $14 million Topco share placement and a concurrent repurchase of up to $450 million in convertible notes, key steps in their proposed merger.

Epsilon Healthcare has emerged from Administration, securing expanded medicinal cannabis manufacturing permits and launching a new pharmacy brand as part of a strategic turnaround and growth plan.

LTR Pharma has expanded patient access to its fast-acting erectile dysfunction treatment SPONTAN by partnering with TerryWhite Chemmart’s extensive pharmacy network, marking a significant step in its commercial rollout and regulatory strategy.